[
  {
    "ts": null,
    "headline": "Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...",
    "summary": "Galapagos NV (GLPG) reports a significant turnaround with an operating profit of EUR295.1 million, while navigating strategic reorganization and leveraging its partnership with Gilead.",
    "url": "https://finnhub.io/api/news?id=552f13fbbd00d6433d83a6a6a0f5868bffed12cf88ad7d83b51ef5da6229fca2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771959700,
      "headline": "Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...",
      "id": 139200975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Galapagos NV (GLPG) reports a significant turnaround with an operating profit of EUR295.1 million, while navigating strategic reorganization and leveraging its partnership with Gilead.",
      "url": "https://finnhub.io/api/news?id=552f13fbbd00d6433d83a6a6a0f5868bffed12cf88ad7d83b51ef5da6229fca2"
    }
  },
  {
    "ts": null,
    "headline": "GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel",
    "summary": "Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.",
    "url": "https://finnhub.io/api/news?id=a2967c8953096887d2a6ab8cd570a25bfd46fd9a13b376ff50faccf3de59e7c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771958220,
      "headline": "GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel",
      "id": 139201652,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.",
      "url": "https://finnhub.io/api/news?id=a2967c8953096887d2a6ab8cd570a25bfd46fd9a13b376ff50faccf3de59e7c4"
    }
  },
  {
    "ts": null,
    "headline": "Galapagos Q4 Earnings Call Highlights",
    "summary": "Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell therapy activities. Management emphasized that the company ended 2025 with roughly €3 billion in cash,",
    "url": "https://finnhub.io/api/news?id=e986e021fb9912e8be4fc1d676906d8169c0916900031408f71aa13df4421bb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771951645,
      "headline": "Galapagos Q4 Earnings Call Highlights",
      "id": 139198897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell therapy activities. Management emphasized that the company ended 2025 with roughly €3 billion in cash,",
      "url": "https://finnhub.io/api/news?id=e986e021fb9912e8be4fc1d676906d8169c0916900031408f71aa13df4421bb1"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=ddc01bb79881dca9f67be93b8791458230d1e58f7be9adc7dcdfd925695bc73a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771950900,
      "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "id": 139213527,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=ddc01bb79881dca9f67be93b8791458230d1e58f7be9adc7dcdfd925695bc73a"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
    "summary": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
    "url": "https://finnhub.io/api/news?id=e339e6785c75aebdc08978bddfa3e9a7547b48dbf07d8f308e18c69c2e0f1bed",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771945440,
      "headline": "Harbor Long-Term Growers ETF Q4 2025 Portfolio Performance",
      "id": 139201097,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e339e6785c75aebdc08978bddfa3e9a7547b48dbf07d8f308e18c69c2e0f1bed"
    }
  },
  {
    "ts": null,
    "headline": "Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls",
    "summary": "Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=eba822f0914bbca1a7b8768433fa841b06f1e51431fd8154143dafe52045874e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771943962,
      "headline": "Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls",
      "id": 139197408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Qualcomm, Booking Holdings upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=eba822f0914bbca1a7b8768433fa841b06f1e51431fd8154143dafe52045874e"
    }
  },
  {
    "ts": null,
    "headline": "Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish",
    "summary": "Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish",
    "url": "https://finnhub.io/api/news?id=4152c90b8d1ca1f532f95718ff18510dafbc8a6f0c60b28cbba897e88c9aeef5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771939820,
      "headline": "Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish",
      "id": 139199422,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4152c90b8d1ca1f532f95718ff18510dafbc8a6f0c60b28cbba897e88c9aeef5"
    }
  },
  {
    "ts": null,
    "headline": "Hypothetical AI Doomsday Scenario Lights Up Wall Street’s HALO Trade",
    "summary": "A post from Citrini Research has drawn widespread attention for its imagining of a 2028 in which AI leads to unceasing white collar layoffs.",
    "url": "https://finnhub.io/api/news?id=56c16108d5eb5a47d2fd047f7f345ab844aea99a82c302a3973fa3968470a445",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771909260,
      "headline": "Hypothetical AI Doomsday Scenario Lights Up Wall Street’s HALO Trade",
      "id": 139198899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "A post from Citrini Research has drawn widespread attention for its imagining of a 2028 in which AI leads to unceasing white collar layoffs.",
      "url": "https://finnhub.io/api/news?id=56c16108d5eb5a47d2fd047f7f345ab844aea99a82c302a3973fa3968470a445"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx",
    "summary": "The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.",
    "url": "https://finnhub.io/api/news?id=f95ba9886f31f13de8e5251b7634904cc76713e8841d5cf595f70712883709d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771909260,
      "headline": "Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx",
      "id": 139198898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The pharma giant already held an 11.5% stake as part of a 2022 effort to co-develop and co-commercialize the cancer treatment anito-cel.",
      "url": "https://finnhub.io/api/news?id=f95ba9886f31f13de8e5251b7634904cc76713e8841d5cf595f70712883709d4"
    }
  }
]